Dr. Peter Papageorgiou

PhD

Research Interests:

Brief Bio:

Dr. Peter Papageorgiou was born in Toronto, but it’s only been a few years since he became familiar with the city again. He has lived and studied in Greece and the United Kingdom, only to move back to Toronto to pursue his love of science; where he discovered a molecule that plays a key role in hypertension that established a physiological connection between the coagulation and sympatho-adrenal systems. Choosing to pursue the project further, focusing on translational research, he applied his in vitro work to animals, and subsequently to a human trial; orchestrating collaborations from cardiology, hematology, nephrology and physiology.

Capstone Project:

In Canada, 10,000 hospitalizations and 3,000 deaths are attributed annually to influenza in older adults (ie. > 65 years old). They are a high-risk group which represents 14% of the Canadian population. The annual uptake of influenza vaccine among older adults remains approximately 70%, which is below the recommended 80% target set by the National Advisory Committee on Immunization (NACI). This sub- optimal vaccine coverage elevates the health risk in this population, with increased comorbidity complications, emergency hospitalization, secondary pneumonia, and flu-related deaths. The Influenza vaccine have been proven to be the most effective way of avoiding influenza-related health complications. The scope of this project is to assess and verify the factors that contribute to vaccination hesitancy (ie. refusal or reluctance for vaccination) in older adults, and subsequently to ideate and co- create a targeted strategy to increase vaccine uptake. This will be conducted in three phases; a quantitative phase, a qualitative phase, and a co-creation of a targeted strategy. The Toronto Translational Framework will be used to discover and define the needs to frame the problem space.

Dr. Peter Papageorgiou

PhD

Research Interests:

Brief Bio:

Dr. Peter Papageorgiou was born in Toronto, but it’s only been a few years since he became familiar with the city again. He has lived and studied in Greece and the United Kingdom, only to move back to Toronto to pursue his love of science; where he discovered a molecule that plays a key role in hypertension that established a physiological connection between the coagulation and sympatho-adrenal systems. Choosing to pursue the project further, focusing on translational research, he applied his in vitro work to animals, and subsequently to a human trial; orchestrating collaborations from cardiology, hematology, nephrology and physiology.

Capstone Project:

In Canada, 10,000 hospitalizations and 3,000 deaths are attributed annually to influenza in older adults (ie. > 65 years old). They are a high-risk group which represents 14% of the Canadian population. The annual uptake of influenza vaccine among older adults remains approximately 70%, which is below the recommended 80% target set by the National Advisory Committee on Immunization (NACI). This sub- optimal vaccine coverage elevates the health risk in this population, with increased comorbidity complications, emergency hospitalization, secondary pneumonia, and flu-related deaths. The Influenza vaccine have been proven to be the most effective way of avoiding influenza-related health complications. The scope of this project is to assess and verify the factors that contribute to vaccination hesitancy (ie. refusal or reluctance for vaccination) in older adults, and subsequently to ideate and co- create a targeted strategy to increase vaccine uptake. This will be conducted in three phases; a quantitative phase, a qualitative phase, and a co-creation of a targeted strategy. The Toronto Translational Framework will be used to discover and define the needs to frame the problem space.